Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Closes Acquisition of Merck's RNAi Assets

Premium

Alnylam Pharmaceuticals this week announced that it has closed its previously announced acquisition of Merck's RNAi assets, including its Sirna Therapeutics subsidiary.

Merck, which acquired Sirna in 2007 for $1.1 billion, unveiled a company-wide restructuring last year that included a reduction in emphasis on platform technologies, including RNAi. In January, the company disclosed that it would sell its RNAi assets to Alnylam in exchange for $25 million in cash and $150 million in stock.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.